A Common Genetic Variation in the 3′-Untranslated Region of the Prothrombin Gene Is Associated With Elevated Plasma Prothrombin Levels and an Increase in Venous Thrombosis

By Swibertus R Poort, Frants R Rosendaal, Pieter H Reitsma, and Rogier M. Bertina

We have examined the prothrombin gene as a candidate gene for venous thrombosis in selected patients with a documented familial history of venous thrombophilia. All the exons and the 5′- and 3′-UT region of the prothrombin gene were analyzed by polymerase chain reaction and direct sequencing in 28 probands. Except for known polymorphic sites, no deviations were found in the coding regions and the 5′-UT region. Only one nucleotide change (a G to A transition) at position 20210 was identified in the sequence of the 3′-UT region. Eighteen percent of the patients had the 20210 AG genotype, as compared with 1% of a group of healthy controls (100 subjects). In a population-based case-control study, the 20210 A allele was identified as a common allele (allele frequency, 12%; 95% confidence interval, 0.5% to 1.8%), which increased the risk of venous thrombosis almost threefold (odds ratio, 2.8; 95% confidence interval, 1.4 to 5.6). The risk of thrombosis increased for all ages and both sexes. An association was found between the presence of the 20210 A allele and elevated prothrombin levels. Most individuals (87%) with the 20210 A allele are in the highest quartile of plasma prothrombin levels (>1.15 U/mL). Elevated prothrombin itself also was found to be a risk factor for venous thrombosis.

© 1996 by The American Society of Hematology

DEEP-VEIN THROMBOSIS is a common disease, with an annual incidence in the general population of approximately 1 per 1,000. Risk factors include both hereditary and acquired conditions. Generally, a tendency toward venous thrombosis could arise from hyperactive coagulation pathways, hypocoagulant mechanisms, or hyperfibrinolysis. Mutations in genes that encode proteins in these pathways play an important role in the predisposition to venous thrombosis. Variant alleles of the genes encoding protein C, protein S, and antithrombin, and antithrombin have been shown to be relatively strong, but uncommon risk factors for thrombosis. Genetic analysis of these genes showed a large heterogeneity of mutations. More recently, a poor anticoagulant response of plasma to activated protein C (APC) due to the presence of a mutant factor V molecule (factor V Leiden) was discovered and is as yet the most common hereditary risk factor for thrombosis known. Recently, some support was obtained for the hypothesis that the clustering of thrombosis in families is due to epistatic effects. Studies in selected families with venous thrombosis indicated that the presence of mutations in two genes may increase the penetrance of the thrombotic disease.

The discovery of genetic risk factors for thrombosis came after the identification of families in whom the thrombophilia segregated with an abnormal result in a plasma test (protein C, protein S, antithrombin, and APC resistance). However, despite the ever growing insight into the processes of coagulation and fibrinolysis, the underlying cause of many inherited thrombotic events remains unsolved. New technologies for genetic analysis of thrombophilic families offer the opportunity to use a direct genetic strategy for identification of other genetic defects involved in inheritable thrombophilia.

We investigated the prothrombin gene as a candidate gene for venous thrombosis. Prothrombin is the precursor of the serine protease thrombin, a key enzyme in the processes of hemostasis and thrombosis, that exhibits procoagulant, anticoagulant, and antifibrinolytic activities. Prothrombin is encoded by a 21-kb-long gene localized on chromosome 11, position 11p11-q12. The prothrombin gene is organized in 14 exons, separated by 13 introns with the 5′ upstream untranslated (UT) region and the 3′ UT region, which may play regulatory roles in gene expression.

The aim of the present study was to perform an analysis of the prothrombin genes of selected subjects with a history of venous thrombophilia using polymerase chain reaction (PCR) and direct sequencing of the coding regions and their flanking splice junctions and the 5′- and 3′-UT regions. One genetic variation in the 3′-UT region of the prothrombin gene, a G to A transition at nucleotide position 20210, was found in 18% of selected patients with a personal and family history of venous thrombosis, in 6% of unselected consecutive patients with a first objectively confirmed episode of deep-vein thrombosis, and in 23% of healthy control subjects. Carriers of the 20210 A allele have higher plasma prothrombin levels than controls with the normal 20210 GG genotype and have a 2.8-fold increased risk of venous thrombosis.

MATERIALS AND METHODS

Subjects In a previous study, we collected detailed information on the occurrence of venous thromboembolic events in the families of 113 probands with a personal and family history of venous thrombophilia. From these, we randomly selected 28 families using the following criteria (1) apart from the proband, there should be at least two symptomatic (preferentially first degree) relatives, and (2) in probands and symptomatic relatives, deficiencies of protein C, protein S, antithrombin, or plasminogen or dysfibrogenemia were excluded. On average, each proband had 2.4 (range, 1 to 6) symptomatic first degree relatives and 1.8 (range, 0 to 5) symptomatic
second degree relatives. All probands and family members gave their informed consent for the study of unexplained familial thrombophilia. It was recently established by DNA analysis that, in this panel of probands, the frequency of the factor V Leiden mutation, which is associated with a poor anticoagulant response to APC, is 40%.

The second group of patients came from a population-based case control study on venous thrombosis, the Leiden Thrombophilia Study (LETS). Briefly, patients were selected from the computer files of the Anticoagulation Clinics in Leiden, Amsterdam, and Rotterdam. In the Netherlands, Anticoagulation Clinics monitor couma treatment in virtually all patients with venous thrombosis in a defined geographic area. Included are 474 unselected and consecutive outpatients younger than 70 years of age who were referred for anticoagulant treatment because of a first, objectively diagnosed episode of deep vein thrombosis. The median time between the occurrence of the deep-vein thrombosis and blood collection was 19 months (range, 6 to 68 months). Ninety-one percent of the eligible patients were willing to take part in the study. The thrombotic patients were asked to find their own healthy control subject according to predefined criteria. This resulted in 474 population control subjects matched for age and sex. The mean age for patients and controls was 47 years (range, 16 to 70 years for patients, range, 16 to 73 years for controls) and the male/female ratio among patients and controls alike was 3:4.

Blotted cotton and laboratory analysis. Blood was collected in tubes containing 0.106 mol/L trisodium citrate. Plasma was prepared by centrifugation for 10 minutes at 2,000g at room temperature and stored at -70°C in 1.5 mL aliquots. High molecular weight DNA was extracted from the white blood cell fraction using standard methods.

Prothrombin activity was measured with a chromogenic method using S-2238 as substrate and Echis carinatus venom as activator. Prothrombin antigen was determined by a Laurell electroimmunoassay. Protein C activity was measured with Cournem protein C (Chromogenix, Molndal, Sweden). An amidolytic heparin cofactor assay (Chromogenix) was used for antithrombin activity measurement. Total protein S antigen was determined by polyclonal enzyme linked immunoassay (ELISA). The results are expressed in units per milliliter, in which 1 U refers to the activity or antigen present in 1 mL of pooled normal plasma.

For the identification of a genetic abnormality (or abnormalities) in the prothrombin gene, DNA from 28 probands with a family history of deep venous thrombosis, we used the PCR followed by direct sequencing. We compared these sequences with those of 5 healthy controls. Genomic DNA was specifically amplified for the identification of a genetic abnormality (or abnormalities) in the prothrombin gene in DNA from 28 probands with a family history of deep venous thrombosis, we used the PCR followed by direct sequencing. We compared these sequences with those of 5 healthy control individuals. Genomic DNA was specifically amplified for the identification of a genetic abnormality (or abnormalities) in the prothrombin gene in DNA from 28 probands with a family history of deep venous thrombosis, we used the PCR followed by direct sequencing. We compared these sequences with those of 5 healthy control individuals.

Results. Our strategy for the identification of sequence variations in the prothrombin gene was to amplify and sequence the exons and their splice junctions and the 5'- and 3'-UT regions of the gene. These regions contain the most likely sites for mutations or polymorphisms that would affect transcription or translation or the stability of the translated product. The PCR products amplified from genomic DNA of the 28 probands and 5 healthy controls were sequenced as reported previously. Except for sequence variations known as neutral polymorphisms, no nucleotide change was found in the 14 exons with their flanking regions and for the 5'- and 3'-UT regions of the prothrombin gene. The primers used in the PCR were derived from the sequence of the gene and are identical to those used in a previous study. The fragments obtained by PCR were purified on 1% ultra low melting temperature agarose gel. The segment of the gel containing the amplified fragment was excised and sequenced with the appropriate primers using the dideoxynucleotide chain termination method. Sequencing reactions were electrophoresed on 40-cm-long 8% polyacrylamide gels. The gels were dried on Whatman 3 mm paper (Whatman, Maidstone, UK) and exposed to an x-ray film. Genetic abnormalities identified by sequencing were confirmed by restriction enzyme digestion of amplified gene fragments. When the abnormality did not create or abolish a restriction site, such a site was created by introducing a nucleotide substitution with a mutant oligonucleotide during amplification. The mutant oligonucleotide was designed with a nucleotide substitution close to the 3' end, such that the combination of the nucleotide substitution and the genetic abnormality created a new restriction enzyme cleavage site. Sequence variations in the prothrombin gene known as neutral polymorphic sites were identified on the basis of previous published data, but are beyond the scope of this study.

Genetic analysis of the FV Leiden mutation (1691 G -> A) was performed as previously described.

Statistical analysis. Odds ratios (ORs) were calculated as a measure of relative risk in the standard unmatched fashion. A 95% confidence interval (CI) was constructed according to Woolf. Generally, the OR estimates the risk of thrombosis when a risk factor is present relative to the reference category.

For risk factor analysis concerning plasma prothrombin values, 48 patients using oral anticoagulant therapy were excluded from the LETS group. To assess a dose response relation, we stratified the prothrombin values of both patients and controls into quartiles and calculated the ORs for the three higher levels relative to the lowest reference level. Adjustment for current oral contraceptive use (yes/no), body mass index (in kilograms per square meter), menopause (yes/no), smoking (yes/no), age, and sex was performed by unconditional logistic regression. Effect modification was assessed by stratified analysis and logistic regression with interaction terms.

Materials. Deoxyribonucleotides, deoxyribonucleotides, and bovine serum albumin were purchased from Pharmacia (Uppsala, Sweden). (α32-P)-dATP (>1,000 Ci/μmol) was obtained from Amersham International (Amersham, UK). Klenow DNA polymerase was from Boehringer Mannheim (Mannheim, Germany). Taq DNA polymerase (Amplitaq) was purchased from Perkin Elmer Cetus (Norwalk, CT). The Chromogenic substrate S-2238 was obtained from Chromogenix (Molndal, Sweden). The Echis carinatus venom was obtained from Sigma (Sigma Chemical, St Louis). Restriction enzymes were obtained from New England Biolabs (Beverly, MA). Oligonucleotides were synthesized on a Cyclone DNA synthesizer (Millipore, Bedford, MA). All other chemicals were of analytical grade from Merck (Darmstadt, Germany).

Results. Our strategy for the identification of sequence variations in the prothrombin gene was to amplify and sequence the exons and their splice junctions and the 5'- and 3'-UT regions of the gene. These regions contain the most likely sites for mutations or polymorphisms that would affect transcription or translation or the stability of the translated product.

The PCR products amplified from genomic DNA of the 28 probands and 5 healthy controls were sequenced as reported previously. Except for sequence variations known as neutral polymorphisms, no nucleotide change was found in the 14 exons with their flanking regions and for the 5'- and 3'-UT regions of the gene. Only one heterozygous nucleotide transition (G to A) at position 20210, the last nucleotide of the 3'-UT region, was found in DNA of 5 of the 28 probands (18%), but not in DNA of the 5 healthy control individuals. For risk factor analysis concerning plasma prothrombin values, 48 patients using oral anticoagulant therapy were excluded from the LETS group. To assess a dose response relation, we stratified the prothrombin values of both patients and controls into quartiles and calculated the ORs for the three higher levels relative to the lowest reference level. Adjustment for current oral contraceptive use (yes/no), body mass index (in kilograms per square meter), menopause (yes/no), smoking (yes/no), age, and sex was performed by unconditional logistic regression. Effect modification was assessed by stratified analysis and logistic regression with interaction terms.

Materials. Deoxyribonucleotides, deoxyribonucleotides, and bovine serum albumin were purchased from Pharmacia (Uppsala, Sweden). (α32-P)-dATP (>1,000 Ci/μmol) was obtained from Amersham International (Amersham, UK). Klenow DNA polymerase was from Boehringer Mannheim (Mannheim, Germany). Taq DNA polymerase (Amplitaq) was purchased from Perkin Elmer Cetus (Norwalk, CT). The Chromogenic substrate S-2238 was obtained from Chromogenix (Molndal, Sweden). The Echis carinatus venom was obtained from Sigma (Sigma Chemical, St Louis). Restriction enzymes were obtained from New England Biolabs (Beverly, MA). Oligonucleotides were synthesized on a Cyclone DNA synthesizer (Millipore, Bedford, MA). All other chemicals were of analytical grade from Merck (Darmstadt, Germany).
The prevalence of carriers of the 20210 A allele among healthy control subjects in the LETS was 2.3%, which corresponds to an allele frequency of 1.2% (95% CI, 0.5% to 1.8%). Table 1 shows a higher prevalence of the 20210 AG genotype among patients (6.2%) than among control subjects (2.3%). Homozygous AA carriers were not found (expected prevalence, 0.014%). The relative risk for thrombosis associated with the 20210 A allele was 2.8 (95% CI, 1.4 to 5.6). This association persisted when controlling for age, sex, current pill use, body mass index, menopause, and smoking. The 20210 A allele was associated with an increased risk for thrombosis both in men and women. We also found that the 20210 A allele increased the risk for all age groups.

To assess the extent to which the increased prothrombin level in itself is a risk factor for venous thrombosis, we stratified the prothrombin levels of patients and control subjects into quartiles (Table 2). The OR increased with increasing prothrombin levels: subjects with a prothrombin level of greater than 1.15 U/mL had a 2.1-fold higher risk than those in the reference category (<0.95 U/mL). The high-risk stratum of greater than 1.15 U prothrombin/mL comprised no less than 31% of the patients and 20% of the control subjects.

Table 3 shows the distribution of the 20210 genotypes.
over the different categories of prothrombin activity. Both in patients and control subjects, around 87% of the individuals with the 20210 AG genotype were in the highest category of prothrombin activity (>1.15 U/mL), whereas less notable differences were observed in individuals with the normal 20210 GG genotype.

**DISCUSSION**

Our study shows that a novel sequence variation in the prothrombin gene (nt 20210 G→A) is a moderate risk factor for venous thrombosis (OR, 2.8; 95% CI, 1.4 to 5.6). The further observations that the 20210 A allele is associated with elevated prothrombin levels, that carriers of this allele have significantly higher prothrombin levels than noncarriers, and that elevated plasma prothrombin itself is also a risk factor for thrombosis suggest that the 20210 A allele acts through the elevated prothrombin levels.

In the LETS, the 20210 A allele was found in 6.3% of consecutive unselected patients with a first episode of deep vein thrombosis, indicating that the 20210 A allele is a relatively common risk factor for venous thrombosis. As expected, a much higher prevalence of 20210 A carriers was found in a group of selected patients with familial venous thrombosis (18%). In 60% of the 20210 A carriers, the 20210 A allele was the only genetic abnormality found, whereas in 40%, the FV Leiden mutation (R506Q) was also present. The prevalence of carriers of the 20210 A allele among

---

**Table 1. Frequencies and Thrombotic Risk for the 20210 G/A Genotypes in the Prothrombin Gene**

<table>
<thead>
<tr>
<th>Genotype (nt 20210)</th>
<th>No. of Patients (%)</th>
<th>No. of Controls (%)</th>
<th>OR&lt;sub&gt;adj&lt;/sub&gt;*</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>GG</td>
<td>442 (93.8)</td>
<td>463 (97.7)</td>
<td>1.0†</td>
<td></td>
</tr>
<tr>
<td>AG</td>
<td>29 (6.2)</td>
<td>11 (2.3)</td>
<td>2.8</td>
<td>1.4-5.6</td>
</tr>
<tr>
<td>AA</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td></td>
</tr>
</tbody>
</table>

* Adjustment for age and sex, current pill use (yes/no), body mass index, in menopause (yes/no) and smoking (yes/no) did not affect these results.
† Reference category.

---

**Table 2. Thrombosis Risk for Plasma Prothrombin Levels**

<table>
<thead>
<tr>
<th>Prothrombin Activity (U/mL)</th>
<th>No. of Patients&lt;sup&gt;+&lt;/sup&gt; (%)</th>
<th>No. of Controls (%)</th>
<th>Total No. (%</th>
<th>OR†</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;0.95</td>
<td>85 (20)</td>
<td>134 (28)</td>
<td>219 (24)</td>
<td>1.0†</td>
<td></td>
</tr>
<tr>
<td>0.95-1.04</td>
<td>107 (25)</td>
<td>125 (26)</td>
<td>232 (26)</td>
<td>1.3</td>
<td>0.9-2.0</td>
</tr>
<tr>
<td>1.05-1.15</td>
<td>102 (24)</td>
<td>118 (25)</td>
<td>220 (24)</td>
<td>1.4</td>
<td>0.9-2.0</td>
</tr>
<tr>
<td>&gt;1.15</td>
<td>132 (31)</td>
<td>97 (20)</td>
<td>229 (25)</td>
<td>2.1</td>
<td>1.5-3.1</td>
</tr>
</tbody>
</table>

* Patients on oral anticoagulant treatment are excluded (n = 48).
† Test for trend, P < .001.
† Reference category.
controls was about 2.3%, corresponding to an allele frequency of 1.2% (95% CI, 0.5% to 1.8%). This is about eightfold higher than for protein C deficiency (0.3%) but about twofold less frequent than the so far most common genetic risk factor for venous thrombosis, the factor V Leiden mutation, which is associated with APC resistance (3% to 5%).

The 20210 A allele was not only found to be a risk factor for thrombosis but also to be associated with elevated prothrombin levels. Interestingly, elevated prothrombin levels were also a risk factor for thrombosis (Table 2). Thus, the prothrombin level may be considered as an effecter, suggesting also that other factors than the 20210 A allele can be responsible for high prothrombin levels. How elevated prothrombin levels may stimulate the formation of venous thrombi is still unclear. They may lead to an imbalance between the procoagulant, anticoagulant, and fibrinolytic system. For instance, when higher concentrations of prothrombin would lead to increased rates of thrombin generation, this might result in excessive growth of fibrin clots.

This study does not show the mechanism(s) by which the 20210 A allele of the prothrombin gene may contribute to higher prothrombin levels. The association found for these two variables (Table 3) and the location of 20210 G to A transition in the 3'-UT region of the prothrombin gene may indicate a relatively higher translation efficiency or higher stability of the transcribed mRNA. The G/A sequence variation is located at the last position of the 3'-UT of or near the cleavage site in the mRNA precursor to which poly A is added. Three conserved sequences in mRNA precursors, located in the vicinity of this site, are required for cleavage and polyadenylation: the AAUAAA sequence, the nucleotide to which poly A is added, and the downstream sequence of this nucleotide. Generally, the nucleotide to which poly A is added is an A, mostly preceded by a C. As a consequence of the G to A transition at position 20210, a CA dinucleotide (instead of GA) has been introduced at or near the cleavage and polyadenylation site. However, in vitro experiments so far do not support a hypothesis in which this nucleotide substitution will result in an increased efficiency of the 3' end formation. Alternatively, it cannot be excluded that the 20210 A allele is in linkage disequilibrium with another sequence variation (that escaped our analysis) that is responsible for the elevated prothrombin levels.

Finally, our approach of sequencing a candidate gene for thrombosis in a panel of probands from families with documented thrombophilia, followed by estimating the risk associated with any observed sequence variation in a population based patient-control study, proved to be useful. This approach seems suitable for unraveling more unknown genetic defects in other candidate genes for inherited thrombophilia.

ACKNOWLEDGMENT

We thank T. Visser and H. de Ronde for skilfull technical assistance; A. van Beek, W. Noteboom, and Y. Bauman-Souverein for secretarial and administrative support; and T. Koster and R. Mensen for collecting blood samples of patients (and their families) and control subjects. We also express our thanks to all patients and control subjects who participated in the Leiden Thrombophilia Study.

REFERENCES


---

Table 3. Number of Individuals With the 20210 GG or AG Genotype for Four Categories of Prothrombin Activity

<table>
<thead>
<tr>
<th>Prothrombin Activity</th>
<th>&lt;0.95</th>
<th>0.95-1.04</th>
<th>1.05-1.15</th>
<th>&gt;1.15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients* (n = 424)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20210 AG</td>
<td>0</td>
<td>1 (3)</td>
<td>2 (7)</td>
<td>24 (90)</td>
</tr>
<tr>
<td>2010 GG</td>
<td>85 (21)</td>
<td>105 (26)</td>
<td>99 (25)</td>
<td>108 (28)</td>
</tr>
<tr>
<td>Control (n = 474)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20210 AG</td>
<td>0</td>
<td>0</td>
<td>2 (18)</td>
<td>9 (82)</td>
</tr>
<tr>
<td>2010 GG</td>
<td>134 (29)</td>
<td>125 (27)</td>
<td>116 (25)</td>
<td>86 (19)</td>
</tr>
<tr>
<td>Total (n = 898)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20210 AG</td>
<td>0</td>
<td>1 (3)</td>
<td>4 (10)</td>
<td>33 (87)</td>
</tr>
<tr>
<td>2010 GG</td>
<td>219 (25)</td>
<td>230 (27)</td>
<td>215 (25)</td>
<td>196 (23)</td>
</tr>
</tbody>
</table>

Values are the number of individuals with percentages in parentheses.

* Patients on oral anticoagulant treatment are excluded (n = 48).
PROTHROMBIN GENE VARIATION AND THROMBOSIS


18 Comp PC, Nixon RR, Cooper MR, Esmon CT Familial protein S deficiency as associated with recurrent thrombosis J Clin Invest 74 2082, 1984


21 Egberg O Inherited antithrombin III deficiency causing thrombophilia Thromb Dutt Haemorrhag 13 516, 1965

22 Ohlin AK, Marlar RA The first mutation identified in the thrombomodulin gene in a 45-year old man presenting with thromboembolic disease Blood 85 330, 1995


24 Bertina RM, van Tilburg NH, de Fouw NJ, Haverkate F Thrombin, a link between coagulation activation and fibrinolysis Ann NY Acad Sci 667 239, 1992

25 Dong QD, Vindigni A, di Cera E An allosteric switch controls the procoagulant and anticoagulant activities of thrombin Proc Natl Acad Sci USA 92 5977, 1995

26 Degen SJF, Dave EJ W Nucleotide sequence of the gene for human prothrombin Biochemistry 26 6165, 1987


28 Engesser L, Brommer EJ, Kluft C, Breet E Elevated plasminogen activation inhibitor (PAI), a cause of thrombophilia? A study in 203 patients with familiar or sporadic venous thrombophilia? Thromb Haemost 62 673, 1989


31 Bertina RM, van der Marel-Nieuwkoop W, Loeliger EA Spectrophotometric assays of prothrombin in plasma of patients using oral anticoagulants Thromb Haemost 42 1296, 1979


33 Poort SR, Michiels JJ, Reitsma PH, Bertina RM Homozygosity for a novel missense mutation in the prothrombin gene causing a severe bleeding disorder Thromb Haemost 72 819, 1994


35 Sanger F, Nicklen S, Coulson AR DNA sequencing with chain-terminating inhibitors Proc Natl Acad Sci USA 74 5463, 1977


38 Woff B On estimating the relation between blood group and disease Am J Hum Genet 19 251, 1955


41 Sheets MD, Ogg SC, Wickens MP Point mutations in A1A-AAA and the poly (A) addition site Effects on the accuracy and efficiency of cleavage and polyadenylation in vitro Nucleic Acids Res 18 5799, 1990

42 McLauchlan J, Gaffney D, Whitton JL, Clemens JB The consensus sequence YGGTGGTTYY located downstream from the AATAAA signal is required for efficient formation of mRNA 3' termini Nucleic Acids Res 13 1347, 1985

43 Moore CL, Skolnik-David H, Sharp PA Analysis of RNA cleavage at the adenovirus-2 L3 polyadenylation site EMBO J 5 1529, 1986

44 Brustuel M, Busslimer M, Strub K Transcription termination and 3' processing The end is in site Cell 41 349, 1985